Developer docs
API playgroundTry for free, no card

Search company profiles

Longevity Vision Fund

Full company profile

uuid00028ac

Namestring
Longevity Vision Fund
Legal namestring
Longevity Vision Holding
Websiteurl
lvf.vc
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Longevity Vision Fund (legal entity: Longevity Vision Holding) is a New York-based venture capital firm founded in 2018 and launched in 2019 by Sergey Young with approximately $100 million in capital. The fund invests exclusively in companies developing technologies intended to extend healthy human lifespan, with stated focus areas including AI-driven drug discovery, diagnostics, regenerative medicine, CRISPR-based therapies, senolytics, epigenetic reprogramming, and longevity-focused health monitoring.

The fund's portfolio of nearly twenty companies is concentrated in early-to-mid-stage biotechnology and digital health. Visible holdings span gene writing and gene therapy (Tessera Therapeutics, 4DMT, Sigilon, Laronde), AI-native drug discovery (Insilico Medicine, Valo Health), early cancer and disease diagnostics (Freenome), organ regeneration (LyGenesis — which raised a $100M Series B), exosome-based therapeutics (exo), programmable medicines (Senda), and biosensors and digital health (Biolinq, eko, Fountain Life). The fund's stated investment thesis is that converging forces — analogous to early personal computing — are creating a new longevity industry.

The business model is conventional venture capital: equity investments in longevity-focused startups, with returns generated through portfolio company exits via IPO or acquisition. Sergey Young provides top-of-funnel credibility through his board seat at the American Federation for Aging Research, support for Healthspan XPRIZE, and authorship of a bestselling book on longevity. The firm has received Fast Company's "World Changing Ideas" recognition. Operating geographies, institutional LP composition, and detailed fund economics are not publicly disclosed.

Short descriptiontext

Longevity Vision Fund is a New York-based venture capital firm investing in longevity and anti-aging biotechnology startups. Deploying approximately $100 million across nearly twenty portfolio companies spanning AI-driven drug discovery, diagnostics, gene therapy, and regenerative medicine.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersNew York, United States
HQ citystring
New York
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
venture capital funding, longevity biotechnology, life sciences investment, biotech portfolio management, anti-aging startups
Industry2 codes
PRIMARYFSANAJAN
SDG / Thematic Sustainable Investment Funds
Financial & Insurance/Private Equity & Venture Capital/Impact / ESG & Sustainable Investment Funds
SECONDARYBPADACAO
Impact Investment & Development Investment Funds
Business & Public Services/International Organizations & Development/International Financial Institutions & Development Banks
NAICS code1 code
  • Other Investment Pools and Funds5259
SIC code1 code
  • Investment Advice6282
Product category
Venture Capital
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Venture Capital Returns
TypeLicensing Royalties
Description

Longevity Vision Fund generates returns through equity investments in longevity-focused startups. The fund was launched with approximately $100 million in capital to deploy across portfolio companies, seeking capital appreciation through exits via IPOs or acquisitions in the longevity biotechnology sector.

techbullion.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Operations, Marketing or Sales, Technology or R&D
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Longevity Vision Fund is a venture capital fund launched in 2019 by Sergey Young with approximately $100 million in capital to deploy as equity investments in early to mid-stage longevity and anti-aging biotechnology startups. The fund backs companies across healthy aging, AI-driven drug discovery, diagnostics, and regenerative medicine, seeking capital appreciation through IPO or acquisition exits.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Portfolio company LyGenesis raised $100 million Series B
+1 more record
Product overview1 text field

Longevity Vision Fund is a venture capital fund that invests in longevity and anti-aging biotechnology companies. The fund was launched in 2019 with approximately $100 million and has built a portfolio of nearly twenty companies focused on healthy aging, AI-driven drug discovery, diagnostics, and regenerative medicine. The portfolio companies include Freenome, Insilico Medicine, Tessera Therapeutics, LyGenesis, and others spanning areas such as epigenetic reprogramming, senolytics, regenerative medicine, and longevity diagnostics. The fund's portfolio page lists 13 portfolio companies including 4DMT, Tessera Therapeutics, EKO, EXO, Sigilon, Insilico Medicine, Freenome, Valo, Senda, Biolinq, LyGenesis, and Laronde.

Product and service1 record
1Longevity Vision Fund
CategoryVenture Capital Fund
Description

A venture capital fund with approximately $100 million of deployable capital that makes equity investments in longevity and anti-aging biotechnology companies. The fund targets early to mid-stage startups developing healthy aging interventions, AI-driven drug discovery, diagnostics, senolytics, regenerative medicine, and longevity-related therapeutics.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2019-01-01
Description

Sergey Young, founder of Longevity Vision Fund, serves on the board of the American Federation for Aging Research, providing strategic alignment and credibility in the longevity investment space.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Longevity Vision Fund supports Healthspan XPRIZE, a major initiative to accelerate development of interventions that extend healthy human lifespan.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Peter Thiel-led VC firm with publicly stated interest in longevity and anti-aging. Invests across biotech and technology with overlap on longevity-themed portfolio companies.

TypeEmerging player
Description

Early-stage VC fund focused on healthspan and longevity. Similar thematic focus but smaller and earlier-stage than Longevity Vision Fund, with potentially overlapping deal flow.

TypeBroad incumbent
Description

Large diversified VC firm with significant biotech and longevity investments. Co-invests in many of the same companies (e.g., Insilico Medicine) but operates across multiple sectors beyond longevity.

TypeDirect peer
Description

Thematic venture firm investing in longevity, biotech, and exponential technologies. Overlapping focus areas, target companies, and LP audience make it a close peer.

TypeBroad incumbent
Description

Major VC firm with a dedicated bio/health fund investing in biotech, digital health, and longevity-adjacent companies. Well-capitalized incumbent competing for the same thesis at scale.

6Y Combinator
TypeBroad incumbent
Description

Accelerator with an active longevity and biotech track record. Funds very early-stage longevity startups that may later become Longevity Vision Fund portfolio candidates.

TypeDirect peer
Description

Venture capital fund focused on aging biology and longevity therapeutics. Competes directly with Longevity Vision Fund for investment opportunities in age-reversal and healthspan companies.

TypeDirect peer
Description

Early-stage venture capital fund dedicated exclusively to longevity and healthspan biotech. Direct competitor for the same longevity-focused founders, investment themes, and LP base as Longevity Vision Fund.

TypeDirect peer
Description

Dedicated longevity-focused investment firm. Comparable thesis on healthspan extension and overlapping investment universe in aging therapeutics.

TypeDirect peer
Description

Early-stage VC fund focused on extending healthy human lifespan. Direct thematic peer competing for similar deal flow in the longevity biotech category.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment21 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Longevity Vision Fund

Venture Capitallvf.vc

Longevity Vision Fund is a New York-based venture capital firm investing in longevity and anti-aging biotechnology startups. Deploying approximately $100 million across nearly twenty portfolio companies spanning AI-driven drug discovery, diagnostics, gene therapy, and regenerative medicine.

What Longevity Vision Fund does

Longevity Vision Fund (legal entity: Longevity Vision Holding) is a New York-based venture capital firm founded in 2018 and launched in 2019 by Sergey Young with approximately $100 million in capital. The fund invests exclusively in companies developing technologies intended to extend healthy human lifespan, with stated focus areas including AI-driven drug discovery, diagnostics, regenerative medicine, CRISPR-based therapies, senolytics, epigenetic reprogramming, and longevity-focused health monitoring.

The fund's portfolio of nearly twenty companies is concentrated in early-to-mid-stage biotechnology and digital health. Visible holdings span gene writing and gene therapy (Tessera Therapeutics, 4DMT, Sigilon, Laronde), AI-native drug discovery (Insilico Medicine, Valo Health), early cancer and disease diagnostics (Freenome), organ regeneration (LyGenesis — which raised a $100M Series B), exosome-based therapeutics (exo), programmable medicines (Senda), and biosensors and digital health (Biolinq, eko, Fountain Life). The fund's stated investment thesis is that converging forces — analogous to early personal computing — are creating a new longevity industry.

The business model is conventional venture capital: equity investments in longevity-focused startups, with returns generated through portfolio company exits via IPO or acquisition. Sergey Young provides top-of-funnel credibility through his board seat at the American Federation for Aging Research, support for Healthspan XPRIZE, and authorship of a bestselling book on longevity. The firm has received Fast Company's "World Changing Ideas" recognition. Operating geographies, institutional LP composition, and detailed fund economics are not publicly disclosed.

Longevity Vision Fund firmographics

Firmographics
Name
Longevity Vision Fund
Legal name
Longevity Vision Holding
Website
https://lvf.vc
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
1–10 employees
Short description
Longevity Vision Fund is a New York-based venture capital firm investing in longevity and anti-aging biotechnology startups. Deploying approximately $100 million across nearly twenty portfolio companies spanning AI-driven drug discovery, diagnostics, gene therapy, and regenerative medicine.
Ownership category
akta.pro rank

Longevity Vision Fund industry classification

Industry
Product category
Venture Capital
NAICS
Other Investment Pools and Funds (5259)
SIC
Investment Advice (6282)
akta.pro industry
PRIMARYFSANAJAN
SDG / Thematic Sustainable Investment Funds
Financial & Insurance/Private Equity & Venture Capital/Impact / ESG & Sustainable Investment Funds
SECONDARYBPADACAO
Impact Investment & Development Investment Funds
Business & Public Services/International Organizations & Development/International Financial Institutions & Development Banks

Keywords

  • Venture capital funding
  • Longevity biotechnology
  • Life sciences investment
  • Biotech portfolio management
  • Anti-aging startups

Where Longevity Vision Fund is headquartered

Location

Headquarters

HQ city
New York
HQ country
United States
HQ region
North America

Markets served

Longevity Vision Fund business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D

Revenue model

  1. Venture Capital Returns: Longevity Vision Fund generates returns through equity investments in longevity-focused startups. The fund was launched with approximately $100 million in capital to deploy across portfolio companies, seeking capital appreciation through exits via IPOs or acquisitions in the longevity biotechnology sector.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Longevity Vision Fund product offering

Product offering

Core offering

Longevity Vision Fund is a venture capital fund launched in 2019 by Sergey Young with approximately $100 million in capital to deploy as equity investments in early to mid-stage longevity and anti-aging biotechnology startups. The fund backs companies across healthy aging, AI-driven drug discovery, diagnostics, and regenerative medicine, seeking capital appreciation through IPO or acquisition exits.

Product overview

Longevity Vision Fund is a venture capital fund that invests in longevity and anti-aging biotechnology companies. The fund was launched in 2019 with approximately $100 million and has built a portfolio of nearly twenty companies focused on healthy aging, AI-driven drug discovery, diagnostics, and regenerative medicine. The portfolio companies include Freenome, Insilico Medicine, Tessera Therapeutics, LyGenesis, and others spanning areas such as epigenetic reprogramming, senolytics, regenerative medicine, and longevity diagnostics. The fund's portfolio page lists 13 portfolio companies including 4DMT, Tessera Therapeutics, EKO, EXO, Sigilon, Insilico Medicine, Freenome, Valo, Senda, Biolinq, LyGenesis, and Laronde.

Differentiator

Problem solved

Functional benefit

Products and services

  • Longevity Vision Fund A venture capital fund with approximately $100 million of deployable capital that makes equity investments in longevity and anti-aging biotechnology companies. The fund targets early to mid-stage startups developing healthy aging interventions, AI-driven drug discovery, diagnostics, senolytics, regenerative medicine, and longevity-related therapeutics.

Quantifiable outcome

  • Portfolio company LyGenesis raised $100 million Series B
  • +1 more outcomes

Companies that use Longevity Vision Fund

Customer profile

Segments1 record

Ideal customer profiles1 record

Longevity Vision Fund technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Longevity Vision Fund partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • American Federation for Aging ResearchcoreStrategic or Co-development Partner · 1 January 2019Sergey Young, founder of Longevity Vision Fund, serves on the board of the American Federation for Aging Research, providing strategic alignment and credibility in the longevity investment space.
  • Healthspan XPRIZEcoreStrategic or Co-development PartnerLongevity Vision Fund supports Healthspan XPRIZE, a major initiative to accelerate development of interventions that extend healthy human lifespan.

Scale indicators4 records

Recent moves5 records

Expansion highlights4 records

Longevity Vision Fund competitors and assessment

Company assessment

Broad incumbents

  • Founders Fund: Peter Thiel-led VC firm with publicly stated interest in longevity and anti-aging. Invests across biotech and technology with overlap on longevity-themed portfolio companies.
  • Khosla Ventures: Large diversified VC firm with significant biotech and longevity investments. Co-invests in many of the same companies (e.g., Insilico Medicine) but operates across multiple sectors beyond longevity.
  • Andreessen Horowitz (a16z Bio): Major VC firm with a dedicated bio/health fund investing in biotech, digital health, and longevity-adjacent companies. Well-capitalized incumbent competing for the same thesis at scale.
  • Y Combinator: Accelerator with an active longevity and biotech track record. Funds very early-stage longevity startups that may later become Longevity Vision Fund portfolio candidates.

Emerging players

  • Civilization Ventures: Early-stage VC fund focused on healthspan and longevity. Similar thematic focus but smaller and earlier-stage than Longevity Vision Fund, with potentially overlapping deal flow.

Direct peers

  • Bold Capital Partners: Thematic venture firm investing in longevity, biotech, and exponential technologies. Overlapping focus areas, target companies, and LP audience make it a close peer.
  • Apollo Ventures: Venture capital fund focused on aging biology and longevity therapeutics. Competes directly with Longevity Vision Fund for investment opportunities in age-reversal and healthspan companies.
  • LongeVC: Early-stage venture capital fund dedicated exclusively to longevity and healthspan biotech. Direct competitor for the same longevity-focused founders, investment themes, and LP base as Longevity Vision Fund.
  • Healthspan Capital: Dedicated longevity-focused investment firm. Comparable thesis on healthspan extension and overlapping investment universe in aging therapeutics.
  • The Longevity Fund: Early-stage VC fund focused on extending healthy human lifespan. Direct thematic peer competing for similar deal flow in the longevity biotech category.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Longevity Vision Fund financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Longevity Vision Fund leadership team

Management profile

Number of profiles

Profiles1 record

Longevity Vision Fund funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Longevity Vision Fund M&A and investment

M&A and investment

M&A

Investments21 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Longevity Vision Fund

What does Longevity Vision Fund do?

Longevity Vision Fund is a venture capital fund launched in 2019 by Sergey Young with approximately $100 million in capital to deploy as equity investments in early to mid-stage longevity and anti-aging biotechnology startups. The fund backs companies across healthy aging, AI-driven drug discovery, diagnostics, and regenerative medicine, seeking capital appreciation through IPO or acquisition exits.

Is Longevity Vision Fund a public or private company?

Longevity Vision Fund is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Longevity Vision Fund founded?

Longevity Vision Fund was founded in 2019. It employs 1 to 10 people.

Where is Longevity Vision Fund based?

Longevity Vision Fund is headquartered in New York, United States, in the North America region.

How does Longevity Vision Fund make money?

One revenue line is on record: venture Capital Returns.

Who are Longevity Vision Fund's main competitors?

Broad incumbents on record are Founders Fund, Khosla Ventures, Andreessen Horowitz (a16z Bio) and Y Combinator. Civilization Ventures is listed as an emerging player. Direct peers are Bold Capital Partners, Apollo Ventures, LongeVC, Healthspan Capital and The Longevity Fund.

Does Longevity Vision Fund have an API?

No public API is recorded for Longevity Vision Fund.

What industry is Longevity Vision Fund in?

Longevity Vision Fund's product category is Venture Capital. Its primary akta.pro industry code is FSANAJAN, SDG / Thematic Sustainable Investment Funds, with a secondary code of BPADACAO, Impact Investment & Development Investment Funds. Its NAICS code is 5259 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Tech TimesSergey Young Investor Profile: Books, Funds, and the Long Bet on HealthSergey Young founded the Longevity Vision Fund, investing in companies like Freenome, Insilico Medicine, and LyGenesis. He is a board member of AFAR and co-founder of the XPRIZE Healthspan initiative, and his book became a bestseller. His later BOLD Longevity Growth Fund aims to scale these ventures.eyeofriyadh.comSergey Young Biography and Why Longevity Investing Stopped Looking So UnusualSergey Young, founder of Longevity Vision Fund, is associated with longevity investing and the Healthspan XPRIZE, a $101 million competition for aging research. Gulf countries are increasing spending on biotechnology and prevention, and the field now overlaps with AI and diagnostics.TechBullionSergey Young Investor: Why Longevity Became Personal for HimSergey Young, a venture investor, launched the Longevity Vision Fund in 2019 with approximately $100 million to invest in companies focused on healthy aging, AI-driven drug discovery, diagnostics, and regenerative medicine. The fund has built a portfolio of nearly twenty companies including Freenome, Insilico Medicine, Fountain Life, Tessera Therapeutics, and LyGenesis, and has gained recognition including Fast Company's 'World Changing Ideas' distinction. Beyond investing, Young serves on the board of the American Federation for Aging Research, supports Healthspan XPRIZE, and authored a bestselling book on longevity science, positioning himself as a leading public advocate for evidence-based approaches to extending healthy years of life.ChosunbizInterview: This man wants to live to 200, in the body of a 25-year-oldSergey Young, founder of Longevity Vision Fund, said he wants to live to 200 in a 25-year-old body. He has invested $100 million in life-extension technologies, with commercial availability for 150-year lifespans in 5-10 years. He aims to make longevity affordable and accessible.FinSMEsSigilon Therapeutics Raises $80.3M in Series B FinancingSigilon Therapeutics completed an $80.3M Series B financing led by CPP Investments, Longevity Vision Fund, and BlackRock, with Flagship Pioneering and Eli Lilly participating. The funds will support a first-in-human trial of its hemophilia A therapy SIG-001, expected in the first half of 2020, bringing total funding to over $195M.South China Morning PostHow science is on a mission to extend the human lifespan – to 1,000?Dr Aubrey de Grey says there is a 50:50 chance that within 17 years science will reach longevity escape velocity, where imperfect rejuvenation therapies buy time to develop better ones. A US$100 million Longevity Vision Fund backs research, and mice have been extended by up to 40% via calorie restriction or telomerase activation.FinSMEsLyGenesis Receives $4M Convertible Debt FinancingLyGenesis, a Pittsburgh-based biotechnology company, completed $4M in private convertible debt financing from Juvenescence and Longevity Vision Fund. The funding will enable its liver regeneration program to enter clinical development, with a Phase 2a trial for end-stage liver disease patients planned in 2020.PR NewswireLyGenesis Closes $4 Million Convertible Debt Financing to Begin Clinical Development of its Liver Regeneration TechnologyLyGenesis, a Pittsburgh-based biotechnology company focused on organ regeneration, completed a $4 million convertible note financing from Juvenescence and Longevity Vision Fund. The funding will enable the company to transition its liver regeneration program into clinical development, with a Phase 2a clinical trial for patients with end stage liver disease planned to begin in 2020. The company's technology uses a patient's lymph nodes as bioreactors to regrow functioning ectopic organs, and the company reports that the approach is generating interest from partner companies seeking enabling technology for their cell therapies.ForbesLongevity Vision Fund: Fueling The Longevity Biotechnology Boom We've Been Waiting ForSergey Young announced the $100 million Longevity Vision Fund at a London forum, planning initial investments in AI for biomarker development, diagnostics, and clinical infrastructure. The fund will co-invest with Bold Capital Partners and Singularity University, aiming to accelerate longevity biotechnology breakthroughs.